VM202

Drug Name: VM202
Company: ViroMed
Location: Seoul, South Korea
Website: http://viromed.co.kr/main/
Drug Type: Gene Therapy
Conditions: ALS, Diabetic Neuropathy, Diabetic Foot Ulcers, Peripheral Arterial Disease
Mechanism Type: Neuroprotection, Axon Regeneration
Mechanism: VM202 uses a pCK vector to deliver hepatocyte growth factor to muscles. The gene therapy strategy aims to stimulate angiogenesis (to provide neuronal trophic support) and the regeneration of damaged peripheral nerve axons.
U.S. Status for ALS: Phase I/II

References:
[1] Sufit, RL et al. Open Label Study to Assess the Safety of VM202 in Subjects with Amyotrophic Lateral Sclerosis Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb 6:1-10.

Last updated June 21st, 2017

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail